Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival

A. M. Brewster, P. Thompson, A. A. Sahin, K. Do, M. Edgerton, J. L. Murray, S. Tsavachidis, R. Zhou, Y. Liu, L. Zhang, Gordon Mills, M. Bondy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Screening mammography results in the increased detection of indolent tumors. We hypothesized that screen- and symptom-detected tumors would show genotypic differences as copy number imbalances (CNI) that, in part, explain differences in the clinical behavior between screen- and symptom-detected breast tumors. We evaluated 850 women aged 40 and above diagnosed with stage I and II breast cancer at the University of TexasMDAnderson Cancer Center between 1985 and 2000 with information available on method of tumor detection (screen vs. symptoms). CNIs in screen- and symptom-detected tumors were identified using high-density molecular inversion probe arrays. Cox proportional modeling was used to estimate the effect of method of tumor detection on disease-free survival after adjusting for age, stage, and the CNIs. The majority of tumors were symptom detected (n = 603) compared with screen detected (n = 247). Copy number gains in chromosomes 2p, 3q, 8q, 11p, and 20q were associated with method of breast cancer detection (P < 0.00001). We estimated that 32% and 63% of the survival advantage of screen detection was accounted for by age, stage, nuclear grade, and Ki67 in women aged 50 to 70 and aged 40 to 87, respectively. In each age category, an additional 20% of the survival advantage was accounted for by CNIs associated with method of detection. Specific CNIs differ between screen- and symptom-detected tumors and explain part of the survival advantage associated with screen-detected tumors. Measurement of tumor genotype has the potential to improve discrimination between indolent and aggressive screendetected tumors and aids patient and physician decision making about use of surgical and adjuvant treatments.

Original languageEnglish (US)
Pages (from-to)1609-1616
Number of pages8
JournalCancer Prevention Research
Volume4
Issue number10
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Disease-Free Survival
Breast Neoplasms
Neoplasms
Survival
Molecular Probes
Mammography
Decision Making
Chromosomes
Genotype
Physicians

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brewster, A. M., Thompson, P., Sahin, A. A., Do, K., Edgerton, M., Murray, J. L., ... Bondy, M. (2011). Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. Cancer Prevention Research, 4(10), 1609-1616. https://doi.org/10.1158/1940-6207.CAPR-10-0361

Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. / Brewster, A. M.; Thompson, P.; Sahin, A. A.; Do, K.; Edgerton, M.; Murray, J. L.; Tsavachidis, S.; Zhou, R.; Liu, Y.; Zhang, L.; Mills, Gordon; Bondy, M.

In: Cancer Prevention Research, Vol. 4, No. 10, 01.10.2011, p. 1609-1616.

Research output: Contribution to journalArticle

Brewster, AM, Thompson, P, Sahin, AA, Do, K, Edgerton, M, Murray, JL, Tsavachidis, S, Zhou, R, Liu, Y, Zhang, L, Mills, G & Bondy, M 2011, 'Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival', Cancer Prevention Research, vol. 4, no. 10, pp. 1609-1616. https://doi.org/10.1158/1940-6207.CAPR-10-0361
Brewster, A. M. ; Thompson, P. ; Sahin, A. A. ; Do, K. ; Edgerton, M. ; Murray, J. L. ; Tsavachidis, S. ; Zhou, R. ; Liu, Y. ; Zhang, L. ; Mills, Gordon ; Bondy, M. / Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 10. pp. 1609-1616.
@article{df3f93d1698d41588a3ad0713263dc27,
title = "Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival",
abstract = "Screening mammography results in the increased detection of indolent tumors. We hypothesized that screen- and symptom-detected tumors would show genotypic differences as copy number imbalances (CNI) that, in part, explain differences in the clinical behavior between screen- and symptom-detected breast tumors. We evaluated 850 women aged 40 and above diagnosed with stage I and II breast cancer at the University of TexasMDAnderson Cancer Center between 1985 and 2000 with information available on method of tumor detection (screen vs. symptoms). CNIs in screen- and symptom-detected tumors were identified using high-density molecular inversion probe arrays. Cox proportional modeling was used to estimate the effect of method of tumor detection on disease-free survival after adjusting for age, stage, and the CNIs. The majority of tumors were symptom detected (n = 603) compared with screen detected (n = 247). Copy number gains in chromosomes 2p, 3q, 8q, 11p, and 20q were associated with method of breast cancer detection (P < 0.00001). We estimated that 32{\%} and 63{\%} of the survival advantage of screen detection was accounted for by age, stage, nuclear grade, and Ki67 in women aged 50 to 70 and aged 40 to 87, respectively. In each age category, an additional 20{\%} of the survival advantage was accounted for by CNIs associated with method of detection. Specific CNIs differ between screen- and symptom-detected tumors and explain part of the survival advantage associated with screen-detected tumors. Measurement of tumor genotype has the potential to improve discrimination between indolent and aggressive screendetected tumors and aids patient and physician decision making about use of surgical and adjuvant treatments.",
author = "Brewster, {A. M.} and P. Thompson and Sahin, {A. A.} and K. Do and M. Edgerton and Murray, {J. L.} and S. Tsavachidis and R. Zhou and Y. Liu and L. Zhang and Gordon Mills and M. Bondy",
year = "2011",
month = "10",
day = "1",
doi = "10.1158/1940-6207.CAPR-10-0361",
language = "English (US)",
volume = "4",
pages = "1609--1616",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival

AU - Brewster, A. M.

AU - Thompson, P.

AU - Sahin, A. A.

AU - Do, K.

AU - Edgerton, M.

AU - Murray, J. L.

AU - Tsavachidis, S.

AU - Zhou, R.

AU - Liu, Y.

AU - Zhang, L.

AU - Mills, Gordon

AU - Bondy, M.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Screening mammography results in the increased detection of indolent tumors. We hypothesized that screen- and symptom-detected tumors would show genotypic differences as copy number imbalances (CNI) that, in part, explain differences in the clinical behavior between screen- and symptom-detected breast tumors. We evaluated 850 women aged 40 and above diagnosed with stage I and II breast cancer at the University of TexasMDAnderson Cancer Center between 1985 and 2000 with information available on method of tumor detection (screen vs. symptoms). CNIs in screen- and symptom-detected tumors were identified using high-density molecular inversion probe arrays. Cox proportional modeling was used to estimate the effect of method of tumor detection on disease-free survival after adjusting for age, stage, and the CNIs. The majority of tumors were symptom detected (n = 603) compared with screen detected (n = 247). Copy number gains in chromosomes 2p, 3q, 8q, 11p, and 20q were associated with method of breast cancer detection (P < 0.00001). We estimated that 32% and 63% of the survival advantage of screen detection was accounted for by age, stage, nuclear grade, and Ki67 in women aged 50 to 70 and aged 40 to 87, respectively. In each age category, an additional 20% of the survival advantage was accounted for by CNIs associated with method of detection. Specific CNIs differ between screen- and symptom-detected tumors and explain part of the survival advantage associated with screen-detected tumors. Measurement of tumor genotype has the potential to improve discrimination between indolent and aggressive screendetected tumors and aids patient and physician decision making about use of surgical and adjuvant treatments.

AB - Screening mammography results in the increased detection of indolent tumors. We hypothesized that screen- and symptom-detected tumors would show genotypic differences as copy number imbalances (CNI) that, in part, explain differences in the clinical behavior between screen- and symptom-detected breast tumors. We evaluated 850 women aged 40 and above diagnosed with stage I and II breast cancer at the University of TexasMDAnderson Cancer Center between 1985 and 2000 with information available on method of tumor detection (screen vs. symptoms). CNIs in screen- and symptom-detected tumors were identified using high-density molecular inversion probe arrays. Cox proportional modeling was used to estimate the effect of method of tumor detection on disease-free survival after adjusting for age, stage, and the CNIs. The majority of tumors were symptom detected (n = 603) compared with screen detected (n = 247). Copy number gains in chromosomes 2p, 3q, 8q, 11p, and 20q were associated with method of breast cancer detection (P < 0.00001). We estimated that 32% and 63% of the survival advantage of screen detection was accounted for by age, stage, nuclear grade, and Ki67 in women aged 50 to 70 and aged 40 to 87, respectively. In each age category, an additional 20% of the survival advantage was accounted for by CNIs associated with method of detection. Specific CNIs differ between screen- and symptom-detected tumors and explain part of the survival advantage associated with screen-detected tumors. Measurement of tumor genotype has the potential to improve discrimination between indolent and aggressive screendetected tumors and aids patient and physician decision making about use of surgical and adjuvant treatments.

UR - http://www.scopus.com/inward/record.url?scp=80053903077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053903077&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-10-0361

DO - 10.1158/1940-6207.CAPR-10-0361

M3 - Article

C2 - 21795423

AN - SCOPUS:80053903077

VL - 4

SP - 1609

EP - 1616

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 10

ER -